RADICAVA ORS Drug Patent Profile

When do Radicava Ors patents expire, and what generic alternatives are available?

Radicava Ors is a drug marketed by Kk Bcj-94 and is included in one NDA. There are ten patents protecting this drug and one Paragraph IV challenge.

This drug has forty-three patent family members in twenty countries.

The generic ingredient in RADICAVA ORS is edaravone. Five suppliers are listed for this compound. Additional details are available on the edaravone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Radicava Ors

A generic version of RADICAVA ORS was approved as edaravone by DR REDDYS on May 6^th, 2024.

Summary for RADICAVA ORS

International Patents:	43
US Patents:	10
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for RADICAVA ORS

Paragraph IV (Patent) Challenges for RADICAVA ORS

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RADICAVA ORS	Oral Suspension	edaravone	105 mg/5 mL	215446	1	2023-04-20

US Patents and Regulatory Information for RADICAVA ORS

RADICAVA ORS is protected by ten US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Kk Bcj-94	RADICAVA ORS	edaravone	SUSPENSION;ORAL	215446-001	May 12, 2022		RX	Yes	Yes	12,310,946
Kk Bcj-94	RADICAVA ORS	edaravone	SUSPENSION;ORAL	215446-001	May 12, 2022		RX	Yes	Yes	12,285,409		Y
Kk Bcj-94	RADICAVA ORS	edaravone	SUSPENSION;ORAL	215446-001	May 12, 2022		RX	Yes	Yes	11,478,450

International Patents for RADICAVA ORS

When does loss-of-exclusivity occur for RADICAVA ORS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

China

Denmark

European Patent Office

Finland

Hungary

Israel

Japan

Mexico

Philippines

Poland

Portugal

Singapore

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering RADICAVA ORS around the world.

Country	Patent Number	Title	Estimated Expiration
Brazil	112021008197
Israel	282773	השעיה של edaravone למינהל אוראלי (Edaravone suspension for oral administration)
China	117379369

RADICAVA ORS: Investment Outlook and Fundamental Analysis

Last updated: February 19, 2026

RADICAVA ORS (edaravone oral suspension) presents a complex investment scenario driven by its therapeutic utility, patent landscape, and market penetration within the amyotrophic lateral sclerosis (ALS) segment. The drug, developed by Mitsubishi Tanabe Pharma Corporation (MTPC), targets oxidative stress, a recognized contributor to motor neuron degeneration in ALS. Its oral formulation aims to improve patient adherence and convenience compared to its intravenous predecessor, RADICAVA (edaravone intravenous infusion).

What is the Current Patent Status for RADICAVA ORS?

The patent portfolio surrounding edaravone and its formulations is critical to RADICAVA ORS's market exclusivity and future revenue streams. MTPC holds multiple patents covering the active pharmaceutical ingredient (API), specific crystalline forms, manufacturing processes, and methods of use for edaravone.

• Core API Patents: Patents covering the edaravone molecule itself have largely expired in key markets like the United States and Europe. For instance, the original patent for edaravone was filed in the late 1980s.
• Formulation Patents: MTPC has secured patents specifically for the oral suspension formulation. These patents are designed to protect the unique characteristics of RADICAVA ORS, such as its stability, bioavailability, and palatability. Key patents include those related to the excipients, particle size, and suspension technology that enable oral administration. The U.S. Patent No. 10,743,929, for example, describes novel oral formulations of edaravone [1]. This patent has a term extending into the late 2030s, providing a significant period of exclusivity for the oral product.
• Method of Use Patents: Further patent protection may exist for specific methods of treating ALS or other neurological conditions with edaravone, though the primary focus for the oral formulation lies in its delivery system and its efficacy in the approved indication.
• Exclusivity Periods: Beyond patent expiry, regulatory exclusivities play a role. In the U.S., new chemical entity (NCE) status grants 5 years of market exclusivity, which would have applied to the initial RADICAVA IV. However, RADICAVA ORS, as a new formulation, may have received different exclusivity terms, often referred to as "hatch-waxman" exclusivity or orphan drug exclusivity if applicable. Orphan drug exclusivity for RADICAVA in the U.S. is for 7 years from approval. The oral suspension was approved in May 2022 [2], implying that its orphan drug exclusivity extends until May 2029.

The expiration of the core API patents opens the door for potential generic competition in the future, but the formulation patents are expected to be the primary bulwark against this for the oral suspension. Any challenge to these formulation patents, or the development of non-infringing formulations by competitors, could significantly impact RADICAVA ORS's market position.

What is the Market Potential and Competitive Landscape for RADICAVA ORS?

The market for ALS therapeutics is characterized by high unmet need and a limited number of approved disease-modifying treatments. RADICAVA ORS competes within this specialized oncology and neurology sub-segment.

• ALS Patient Population: The global prevalence of ALS is estimated to be between 2-5 cases per 100,000 people. In the United States, approximately 16,000 people are living with ALS [3]. This relatively small but growing patient population defines the addressable market.
• Market Penetration of RADICAVA (IV): Prior to the oral suspension, RADICAVA IV was one of the few FDA-approved treatments shown to slow functional decline in ALS patients. Its uptake, however, was somewhat tempered by the challenges associated with intravenous administration, requiring regular clinic visits and infusions.
• RADICAVA ORS as a Differentiator: The oral formulation is designed to capture patients who were hesitant or unable to access the IV formulation due to administration complexities. This includes patients with greater functional impairment, those living further from infusion centers, or those seeking greater convenience. MTPC reported that approximately 40% of eligible RADICAVA IV patients were not on therapy due to administration challenges [4]. RADICAVA ORS aims to convert a portion of these patients to therapy.
• Key Competitors:
  • Riluzole: An older, oral medication that has demonstrated modest survival benefits in ALS. It is widely available generically.
  • Teva Pharmaceuticals' Teva-Riluzole: A generic version of riluzole.
  • Radicava (edaravone IV): The intravenous formulation of edaravone, still relevant for patients who prefer or require IV administration.
  • AMX0035 (Relyvrio/Albrioza): Developed by Amylyx Pharmaceuticals, this combination therapy (sodium phenylbutyrate and taurursodiol) gained U.S. approval in 2022 based on promising trial data suggesting slowing of functional decline and survival benefits. However, its approval status has faced scrutiny, with a recent advisory committee recommending its withdrawal from the market due to insufficient confirmatory trial data [5].
  • NurOwn (deuterated dexamethasone): A mesenchymal stem cell therapy in development by BrainStorm Cell Therapeutics, which has faced clinical trial hurdles and regulatory uncertainty.
  • Biogen's Qalsody (tofersen): An antisense oligonucleotide approved for a specific genetic subset of ALS patients (those with mutations in the superoxide dismutase 1 gene, SOD1-ALS). This targets a specific genetic cause and is not a broad-spectrum ALS therapy.

The competitive landscape is dynamic. While edaravone's mechanism of targeting oxidative stress is distinct, the ultimate measure of success for new ALS therapies is their ability to demonstrate a statistically significant and clinically meaningful impact on disease progression and survival. RADICAVA ORS's success will be measured against existing therapies and future entrants, with the oral convenience being a primary differentiator in the short to medium term.

What are the Financial Performance and Growth Projections for RADICAVA ORS?

Analyzing the financial performance of RADICAVA ORS requires an examination of MTPC's reported revenues, considering the contributions from both the IV and oral formulations, and understanding the ramp-up in sales for the newer oral product.

• RADICAVA (IV) Sales: Prior to the oral launch, RADICAVA IV achieved significant sales. For fiscal year 2021, MTPC reported global sales of RADICAVA/Radicut (the Japanese brand name) of approximately ¥85.8 billion (USD 780 million at an approximate exchange rate) [6].
• RADICAVA ORS Launch Impact: The U.S. launch of RADICAVA ORS occurred in May 2022. Initial sales figures reflect the ramp-up phase and physician adoption. In the first quarter of fiscal year 2023 (ending June 30, 2022), sales of RADICAVA ORS in the U.S. were reported as ¥1.5 billion (approximately USD 13.6 million) [7]. By the third quarter of fiscal year 2023 (ending December 31, 2022), consolidated net sales of edaravone products (including IV and ORS) reached ¥28.6 billion (approximately USD 210 million) [8].
• Growth Trajectory: The expectation is for RADICAVA ORS to gradually replace a portion of the IV market and attract new patients. The long-term growth will depend on market penetration, competitive dynamics, and the potential for expanded indications or improved efficacy data. Analyst projections often anticipate a steady increase in sales as physician and patient familiarity grows and as the oral formulation proves its value proposition.
• R&D Investment: MTPC continues to invest in R&D, including potential further studies related to edaravone, which could impact future market positioning.
• Global Market Expansion: While the U.S. is a primary market, MTPC also markets edaravone in Japan, China, and other regions, each with its own market dynamics and regulatory pathways.

The financial outlook is contingent on MTPC's ability to effectively market the oral formulation, demonstrate its clinical utility beyond mere convenience, and navigate the evolving ALS treatment landscape.

What are the Key Risks and Opportunities Associated with RADICAVA ORS?

RADICAVA ORS presents both significant opportunities and considerable risks for stakeholders.

Opportunities

• Improved Patient Adherence and Access: The oral formulation is the primary opportunity. By removing the need for intravenous infusions, RADICAVA ORS is expected to improve adherence and expand access to edaravone therapy for a broader patient population, potentially converting patients previously unable to access or tolerate the IV version.
• Market Share Capture: With limited effective treatments for ALS, the oral formulation has the potential to capture a substantial share of the addressable market, especially if it demonstrates comparable or superior efficacy to the IV form with the added benefit of convenience.
• Potential for Expanded Indications: While currently approved for ALS, MTPC may explore or existing patents might cover other neurodegenerative conditions where oxidative stress plays a role, opening new market avenues.
• Lifecycle Management: The oral formulation represents successful lifecycle management, extending the commercial life of the edaravone franchise.

Risks

• Competition: The ALS therapeutic landscape is evolving rapidly. The introduction of new treatments, including gene therapies and combination approaches, could diminish the relative advantage of edaravone. The approval of Qalsody for SOD1-ALS, though for a specific sub-population, highlights this trend.
• Generic Competition: As core edaravone patents expire, the threat of generic competition for the API will persist. While formulation patents offer protection for RADICAVA ORS, the development of non-infringing generic oral formulations remains a long-term risk.
• Clinical Efficacy Perception: The perceived clinical benefit of edaravone, particularly its impact on slowing disease progression, has been a subject of discussion. If future studies or real-world evidence do not strongly support a meaningful clinical benefit, uptake could be limited. The withdrawal recommendation for Relyvrio in the U.S. by an FDA advisory committee underscores the high bar for demonstrating efficacy in ALS.
• Regulatory Scrutiny and Market Access: Pharmaceutical products, especially in complex disease areas, face ongoing regulatory review and market access challenges related to pricing, reimbursement, and physician prescribing patterns.
• Manufacturing and Supply Chain Issues: As with any pharmaceutical product, there is a risk of disruptions in manufacturing or supply chain issues that could impact availability and sales.
• Patent Litigation: MTPC may face patent litigation from generic manufacturers seeking to challenge the validity or scope of the formulation patents, which could lead to early market entry for generics.

Key Takeaways

RADICAVA ORS (edaravone oral suspension) represents a strategic evolution for Mitsubishi Tanabe Pharma Corporation in the ALS market. Its primary investment thesis hinges on the enhanced patient convenience offered by the oral formulation, which aims to broaden access and improve adherence compared to its intravenous predecessor. The drug's market exclusivity is primarily protected by formulation patents, extending into the late 2030s, which are crucial barriers against generic entry for the oral product. While the core API patents have expired, the formulation patents provide a significant runway for revenue generation.

The competitive landscape for ALS therapies is dynamic and crowded, with existing treatments like riluzole and newer entrants targeting specific genetic mechanisms or employing novel combination approaches. RADICAVA ORS must demonstrate its value proposition against this backdrop. Initial sales figures indicate a gradual ramp-up, with continued growth projected as physician and patient adoption increases. However, risks associated with evolving competitive therapies, potential future generic challenges to formulation patents, and ongoing scrutiny of clinical efficacy remain significant considerations for investors.

Frequently Asked Questions

1. When do the primary patents protecting RADICAVA ORS expire in the United States? The key patents protecting the oral suspension formulation of edaravone, such as U.S. Patent No. 10,743,929, are projected to expire in the late 2030s.

2. What is the estimated prevalence of ALS globally and in the United States? The global prevalence of ALS is estimated between 2-5 cases per 100,000 people. In the United States, approximately 16,000 individuals are living with ALS.

3. How does RADICAVA ORS aim to differentiate itself from existing ALS treatments? RADICAVA ORS differentiates itself through its oral administration, which offers improved convenience and adherence compared to the intravenous formulation of edaravone and eliminates the need for regular clinic visits for infusions.

4. What is the potential market size for RADICAVA ORS, considering the limitations of intravenous administration of the original drug? Mitsubishi Tanabe Pharma Corporation estimated that approximately 40% of eligible RADICAVA IV patients were not on therapy due to administration challenges, indicating a substantial segment of the market that RADICAVA ORS aims to capture.

5. Besides patent protection, what other forms of market exclusivity does RADICAVA ORS benefit from in the United States? RADICAVA ORS benefits from orphan drug exclusivity in the United States, which provides 7 years of market exclusivity from its approval date of May 2022, extending until May 2029.

Citations

[1] United States Patent 10,743,929. (2020). Oral formulations of edaravone. Google Patents. [2] U.S. Food and Drug Administration. (2022, May 5). FDA approves new oral formulation of Radicava (edaravone) for treatment of amyotrophic lateral sclerosis (ALS). [Press Release]. [3] National Institute of Neurological Disorders and Stroke. (n.d.). Amyotrophic Lateral Sclerosis (ALS) Fact Sheet. [4] Mitsubishi Tanabe Pharma Corporation. (2022). Investor Relations Presentation. [5] U.S. Food and Drug Administration. (2024, March 20). FDA Advisory Committee Meeting Summary: Neuronal and Cognitive Drugs Advisory Committee. [6] Mitsubishi Tanabe Pharma Corporation. (2022). FY2021 Financial Results Presentation. [7] Mitsubishi Tanabe Pharma Corporation. (2022). Q1 FY2023 Earnings Briefing Materials. [8] Mitsubishi Tanabe Pharma Corporation. (2023). Q3 FY2023 Earnings Briefing Materials.